U.S. and Europe In-vivo Pharmacology Market, By Service Type, By Application, By End User

Description

U.S. and Europe In-vivo Pharmacology Market is estimated to be valued at USD 21,793.6 Mn in 2026 and is expected to reach USD 35,688.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.3% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 21,793.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.30%	2033 Value Projection:	USD 35,688.4 Mn

The U.S. and Europe in-vivo pharmacology market comprises the use of living animal models to evaluate safety, efficacy, pharmacokinetic, and pharmacodynamic parameters of potential drugs. It functions as a bridge between in-vitro screening, early-stage drug discovery and human trials for further validation and safety.

The U.S. and Europe in-vivo pharmacology market is driven by substantial R&D investment from biopharmaceutical organizations in these regions, significant regulatory support systems, presence of academic research institutions and a highly competitive environment within the market. Furthermore, increasing prevalence of diseases, such as cancer and neurological disorders, which often pose complexity during development phase, further accentuates the role of the in-vivo pharmacology segment in the U.S. and Europe in-vivo pharmacology market.

Market Dynamics

The U.S. and Europe in-vivo pharmacology market is fueled by the growing R&D spending by pharma and biopharma companies, rising incidences of chronic and rare diseases and increasing demand for the validation of novel drugs via in-vivo assessment. Regulatory requirements from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for comprehensive in-vivo studies before clinical trials, coupled with the expanding pipelines of biologics, cell therapies, and gene therapies, continue to strengthen the demand for advanced in-vivo pharmacology services.

However, a number of constraints are present in the market, such as rising ethical concerns and public attention about the animal testing, high cost for animal models, development of sophisticated animal research infrastructure, and specialized animal models. Nevertheless, expanding outsourcing to contract research organizations (CROs) and technological advancements such as humanized animal models, patient-derived xenografts, and non-invasive in-vivo imaging are creating significant opportunities by improving translational accuracy, operational efficiency, and the overall value of preclinical pharmacology studies.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the U.S. and Europe in-vivo pharmacology market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Charles River Laboratories, Labcorp Drug Development, Pharmaron, ICON plc, Parexel International, Eurofins Scientific, Evotec, Inotiv, Taconic Biosciences, and Altasciences
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The U.S. and Europe in-vivo pharmacology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. and Europe in-vivo pharmacology market

Market Segmentation

Service Type Insights (Revenue, USD Mn, 2021 - 2033)
Toxicology studies
PK and PD Studies
Maximum Tolerated Dose Studies
Biomarkers Testing and Bio analysis
Animal Disease Models
ADME studies
Others
Application Insights (Revenue, USD Mn, 2021 - 2033)
Oncology
Inflammation and Immunology
Cardiology
Neurology
Pain Management
Fibrosis
Metabolic Diseases
Respiratory Diseases
Infectious Diseases
Others
End User Insights (Revenue, USD Mn, 2021 - 2033)
Biotechnology and Pharmaceutical Companies
Contract Research Organizations (CROs)
Others
Key Players Insights
Charles River Laboratories
Labcorp Drug Development
Pharmaron
ICON plc
Parexel International
Eurofins Scientific
Evotec
Inotiv
Taconic Biosciences
Altasciences

Product Code: CMI9803

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- U.S. and Europe In-vivo Pharmacology Market, By Service Type
- U.S. and Europe In-vivo Pharmacology Market, By Application
- U.S. and Europe In-vivo Pharmacology Market, By End User

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Industry Trends

4. U.S. and Europe In-vivo Pharmacology Market, By Service Type, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Toxicology studies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
PK and PD Studies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Maximum Tolerated Dose Studies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Biomarkers Testing and Bio analysis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Animal Disease Models
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
ADME studies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. U.S. and Europe In-vivo Pharmacology Market, By Application, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Inflammation and Immunology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Cardiology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Neurology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Pain Management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Fibrosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Metabolic Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Respiratory Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. U.S. and Europe In-vivo Pharmacology Market, By End User, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Biotechnology and Pharmaceutical Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Competitive Landscape

Company Profile
- Charles River Laboratories
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Labcorp Drug Development
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Pharmaron
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- ICON plc
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Parexel International
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Eurofins Scientific
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Evotec
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Inotiv
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Taconic Biosciences
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Altasciences
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies

8. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

9. References and Research Methodology

References
Research Methodology
About us